BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report January – September 2018

Thu, Nov 08, 2018 08:00 CET

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projectsJuly – September 2018 · Net revenues for the period amounted to SEK 94.0 million (31.5) · Operating profit amounted to SEK 33.1 million (0.6) · Profit for the period amounted to SEK 25.9 million (-0.1) · Earnings per share were SEK 0.29 (0.00) · Cash flow from operating activities amounted to SEK -31.5 million (-23.6) January – September 2018 · Net revenues for the period amounted to SEK 198.6 million (89.7) · Operating profit

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report January – September 2018

Subscribe

Media

Share

About Us

Interim Report January – September 2018

Subscribe

Media